Nanomedicine Market by Modality, Application, and Indication : Global Opportunity Analysis and Industry Forecast, 2021–2030

Nanomedicine Market by Modality, Application, and Indication : Global Opportunity Analysis and Industry Forecast, 2021–2030

  • March 2022 •
  • 215 pages •
  • Report ID: 6269622 •
  • Format: PDF
Nanomedicine Market by Modality (Diagnostics and Treatment), Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, Implants, and Others), and Indication (Clinical Oncology, Infectious Diseases, Clinical Cardiology, Orthopedics, Neurology, Urology, Ophthalmology, Immunology And Others): Global Opportunity Analysis and Industry Forecast, 2021–2030


The global nanomedicine market was valued at $171,695.33 million in 2020, and is projected to reach $393,046.52 million by 2030, registering a CAGR of 9.2% from 2021 to 2030.
Nanomedicine is a branch of medicine that uses tools and knowledge of nanotechnology for prevention and treatment of different diseases. Nanomedicines are multifunctional drugs with programmable properties that find applications in monitoring, construction, repair, and control of biological systems at the molecular level using nanodevices and nanoparticles. They have the potential to revolutionize the current scenario of detection of disease, its treatment, and diagnosis methods.
Emerging innovative technologies for drug delivery, advantages of nanomedicine in various healthcare applications, and rise in government support and funding drive growth of the market. Moreover, growth in need for safe and cost-effective therapies also contribute toward growth of the market. However, long approval process and risks associated with nanomedicines (environmental impact) are expected to hinder the market growth. Conversely, increase in out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are expected to offer lucrative opportunities for market expansion during the forecast period.
The nanomedicine market is segmented on the basis of modality, application, indication and region. On the basis of modality, the market is segmented into diagnostics and treatment. On the basis of application, the market is segmented into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. On the basis of indication, the market is segmented into clinical oncology, infectious diseases, clinical cardiology, orthopedics, neurology, urology, ophthalmology, immunology and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
? This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
? An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
? A comprehensive analysis of the factors that drive and restrain the growth of the nanomedicine market is provided.
? An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
? Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS
- By MODALITY
- Diagnostics
- Treatment
- By APPLICATION
- Drug Delivery
- Diagnostic Imaging
- Vaccines
- Regenerative Medicine
- Implants
- Others
- By INDICATION
- Clinical Oncology
- Infectious Diseases
- Clinical Cardiology
- Orthopedics
- Neurology
- Urology
- Ophthalmology
- Immunology
- Others

- By REGION
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

KEY MARKET PLAYERS
• Abbott Laboratories
• DiaSorin S.p.A.
• General Electric Company
• Invitae Corporation
• Johnson & Johnson
• Leadient BioSciences Inc.
• Mallinckrodt plc
• Merck & Co., Inc.
• Pfizer Inc.
• Teva Pharmaceuticals Ltd.